Core Viewpoint - ALX Oncology Holdings Inc. is set to report its second quarter 2025 financial results and provide a business update on August 12, 2025, after market close [1] Group 1: Financial Results Announcement - The company will host a teleconference in conjunction with its financial results press release [1] - The webcast for the financial results will take place on August 12, 2025, at 1:30 PM PT / 4:30 PM ET [2] - Access to the conference call can be made via phone or through a dedicated link for instant telephone access [3] Group 2: Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing novel therapies for cancer treatment [4] - The lead therapeutic candidate, evorpacept, is being evaluated in multiple ongoing clinical trials across various cancer indications [4] - The second pipeline candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate expected to enter Phase 1 trials in mid-2025 [4]

Summary of Conference Call Company and Industry - The conference call discusses ALX Oncology, focusing on their drug development programs, particularly in the oncology sector, including anti-CD47 antibodies and antibody-drug conjugates (ADCs) targeting EGFR. Core Points and Arguments 1. **Current Drug Development**: ALX Oncology is developing an anti-CD47 antibody, aboricept, which is unique due to its dead Fc mechanism, showing no on-target related issues that have affected similar drugs in the past [6][10][12]. 2. **Clinical Studies**: The company has five positive clinical studies supporting their initial hypothesis from 2015, with ongoing studies in breast and colorectal cancers [9][17]. 3. **New ADC Program**: ALX is working on a new ADC targeting EGFR, which is still in early stages but shows promise. The company aims to be first and best in class against this validated target [3][10]. 4. **Breast Cancer Study**: A randomized study is being launched for patients post-HER2 treatment, showing a 55% overall response rate (ORR) in previous studies. The study will compare the combination of vorprecept and Herceptin with chemotherapy [19][33]. 5. **Colorectal Cancer Study**: The company is initiating a study combining their drug with cetuximab in colorectal cancer, addressing a significant unmet need in this area [60][61]. 6. **EGFR ADC Development**: ALX is innovating in the ADC space by optimizing the payload, linker, and antibody to minimize on-target toxicity, particularly skin toxicity, which has plagued previous EGFR ADCs [82][84]. 7. **Preclinical Success**: In non-human primate studies, ALX has dosed up to 10 mg/kg without observing skin toxicity, indicating a potential therapeutic window for their ADC [86][102]. 8. **Financial Position**: The company reported approximately $100 million in cash at the end of Q1, with plans to manage expenses effectively while executing their studies [110][111]. Other Important Content 1. **Patient Selection**: The company emphasizes the importance of selecting HER2 positive patients for their studies, utilizing ctDNA as a surrogate marker for patient eligibility [51][53]. 2. **Market Strategy**: ALX is focused on executing their studies while exploring potential partnerships for their drugs, particularly after positive data presentations at ASCO [117][118]. 3. **Future Data Readouts**: Interim data for the breast cancer study is expected in the second half of 2026, while colorectal study data may be available in the first half of 2026 [80][115]. This summary encapsulates the key points discussed during the conference call, highlighting ALX Oncology's strategic focus on innovative cancer therapies and their clinical development pipeline.

Core Insights - ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing novel therapies for cancer treatment and improving patient survival [2] Group 1: Company Overview - ALX Oncology's lead therapeutic candidate, evorpacept, shows promise as a foundational therapy for future immuno-oncology treatments and is currently undergoing multiple clinical trials across various cancer indications [2] - The second pipeline candidate, ALX2004, is an innovative EGFR-targeted antibody-drug conjugate with a unique mechanism of action, expected to enter Phase 1 trials in mid-2025 [2] Group 2: Upcoming Events - Management will participate in the Jefferies 2025 Global Healthcare Conference, scheduled for June 5, 2025, at 1:25 PM ET in New York, NY [1] - A live webcast of the event will be available on ALX Oncology's website, with a replay accessible for up to 90 days post-event [1]

ALX2004 Program Overview - ALX2004 is an EGFR-targeted ADC with a DAR of 8, utilizing a topoisomerase I inhibitor (Top1i) payload, with IND cleared in April 2025[13, 98] - ALX2004 is designed to maximize the therapeutic window and overcome toxicity challenges, with a focus on EGFR-expressing solid tumors[14, 99] - ALX2004's Phase 1a dose escalation trial is planned to start in mid-2025, targeting NSCLC, CRC, HNSCC, and ESCC[14, 99] ALX2004 Design and Preclinical Data - ALX2004's EGFR antibody binding epitope is selected to minimize off-tumor skin toxicities, and its affinity is tuned to maximize the therapeutic window[20] - The linker-payload is designed for lysosomal cleavage, similar to deruxtecan ADCs, with improved linker-antibody stability to minimize off-tumor payload release[20] - Preclinical data demonstrates dose-dependent activity across a range of tumors and EGFR expression levels, with a differentiated safety profile in NHP toxicity studies, showing no EGFR-related skin toxicity at clinically relevant doses[24] - In preclinical studies, ALX2004 demonstrated superior anti-tumor activity compared to DXd ADCs in CDX mouse models, showing improved bystander effect[47, 49] Clinical Development Plan - The Phase 1 trial is rationally designed around tumor types with established sensitivity to EGFR-directed therapies, including HNSCC, CRC, NSCLC, and ESCC, representing over 250,000 patient prevalence in the US[87] - The Phase 1 clinical development plan includes dose escalation (Phase 1a, up to 40 patients), dose exploration (up to 50 patients), and dose expansion (Phase 1b, up to 80 patients)[89, 90, 91] - ALX Oncology anticipates initial safety data for ALX2004 in EGFR-expressing solid tumors in the first half of 2026[101]

Summary of ALX Oncology Holdings (ALXO) Conference Call Company Overview - **Company**: ALX Oncology Holdings (ALXO) - **Focus**: Development of ALX2004, a differentiated antibody-drug conjugate (ADC) targeting EGFR Key Points and Arguments Industry and Product Development - **ADC Focus**: ALX2004 is designed to maximize therapeutic window and overcome historical toxicity challenges associated with EGFR-targeted ADCs [5][6][10] - **Clinical Pipeline**: The company is advancing its ADC in combination with anti-cancer antibodies, specifically targeting breast and colorectal cancers [4][5] - **IND Clearance**: ALX2004 has received Investigational New Drug (IND) clearance, with plans to launch a Phase I trial in mid-2025 [5][7] Scientific Rationale - **Payload and Linker Design**: ALX2004 utilizes a proprietary topoisomerase one inhibitor payload, designed to minimize off-target toxicity while maximizing tumor cell killing [17][20] - **Immunogenic Cell Death**: The payload triggers immunogenic cell death, potentially enhancing long-term tumor control through adaptive immune response [18][28] - **Optimized Antibody**: The antibody component is designed to block EGFR signaling and bind to a unique epitope, potentially overcoming resistance to existing therapies [30][32] Clinical Development Plans - **Phase I Study**: The study will focus on four tumor types: head and neck squamous cell carcinoma, colorectal cancer, non-small cell lung cancer, and esophageal squamous cell carcinoma, targeting patients with relapsed or refractory disease [40][41] - **Safety and Efficacy Goals**: Initial safety data is expected in the first half of 2026, with an emphasis on establishing a recommended dosing schema [42][43] Competitive Landscape - **Market Positioning**: ALX Oncology aims to be a leader in the ADC space targeting EGFR, which currently lacks an approved drug [43][85] - **Comparison with Competitors**: The company is aware of other ADCs in development, such as MRG003, but believes its optimized design gives it a competitive edge [85] Additional Important Insights - **Preclinical Data**: Robust preclinical data supports the efficacy and safety profile of ALX2004, with encouraging results in various tumor models [14][34] - **Toxicity Management**: The design aims to avoid common toxicities seen in previous EGFR-targeted ADCs, such as skin toxicity and interstitial lung disease [14][72] - **Funding and Capital Allocation**: The company has sufficient cash to fund its ongoing studies into 2024, with plans to explore additional capital options as needed [51][52] This summary encapsulates the critical aspects of ALX Oncology's conference call, highlighting the company's strategic focus on developing ALX2004 and its potential impact on the oncology market.

Core Insights - ALX Oncology is advancing ALX2004, a potential best- and first-in-class antibody-drug conjugate (ADC) targeting EGFR-expressing solid tumors, designed to maximize therapeutic efficacy while minimizing toxicity [1][2] - The U.S. FDA has cleared the IND application for ALX2004, with clinical studies set to begin in mid-2025 and initial safety data expected in the first half of 2026 [1][6] - The company plans to initiate trials for its lead therapy, evorpacept, in breast and colorectal cancers around the same time, with significant milestones anticipated in 2026 [1] ALX2004 Development Overview - ALX2004 is developed using a proprietary linker-payload platform, featuring an affinity-tuned EGFR antibody and a stable linker-Top1i payload, aimed at enhancing anti-tumor activity and reducing toxicity [3][4] - Preclinical data indicates that ALX2004 has superior stability and a favorable safety profile compared to other ADCs, showing dose-dependent activity across various tumors and EGFR expression levels [5] Clinical Trial Plans - The Phase 1 clinical trial for ALX2004 will target EGFR-expressing solid tumors, including non-small cell lung cancer and colorectal cancer, focusing on patients with relapsed or refractory cancers [6] - The trial is expected to begin in mid-2025, with initial safety data anticipated in the first half of 2026 [1][6]

Core Insights - ALX Oncology will host a webcast on May 20, 2025, to provide updates on ALX2004, a potentially first-in-class antibody-drug conjugate designed to treat cancer [1][3] - ALX2004 is developed in-house and utilizes a proprietary topoisomerase I inhibitor payload platform, targeting EGFR-expressing tumors to enhance anti-tumor activity [2] Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing novel therapies for cancer treatment, with its lead candidate evorpacept currently in multiple clinical trials [4] - ALX2004 is expected to enter Phase 1 trials in mid-2025, showcasing a differentiated mechanism of action [4]

Financial Performance - Net loss for the three months ended March 31, 2025, was $30,754,000, compared to a net loss of $35,581,000 for the same period in 2024, representing a reduction of about 13.5%[18]. - The company reported a total comprehensive loss of $30,911,000 for the three months ended March 31, 2025, compared to $35,809,000 for the same period in 2024, a reduction of approximately 13.5%[21]. - The net loss for the three months ended March 31, 2025, was $30.8 million, compared to a net loss of $35.6 million for the same period in 2024, reflecting a 13.5% improvement[44]. - For the three months ended March 31, 2025, the net loss was $30.8 million, a decrease of 14% compared to a net loss of $35.6 million for the same period in 2024[113]. - The accumulated deficit reached $651.9 million as of March 31, 2025, with expectations of continued net losses in the foreseeable future[139]. Assets and Liabilities - Total current assets decreased from $134,352,000 as of December 31, 2024, to $102,532,000 as of March 31, 2025, a decline of approximately 23.7%[16]. - Total liabilities decreased from $34,157,000 as of December 31, 2024, to $32,605,000 as of March 31, 2025, a decrease of approximately 4.5%[16]. - Total stockholders' equity decreased from $113,618,000 as of December 31, 2024, to $88,295,000 as of March 31, 2025, a decline of approximately 22.3%[16]. - As of March 31, 2025, the company's cash, cash equivalents, and investments totaled $107.0 million, down from $131.3 million as of December 31, 2024[42]. - The fair value of cash equivalents and available-for-sale investments decreased to $105.3 million as of March 31, 2025, from $129.2 million as of December 31, 2024[48]. Research and Development - Research and development expenses decreased from $31,717,000 in Q1 2024 to $23,888,000 in Q1 2025, a decrease of approximately 24.7%[18]. - Total research and development expenses for the three months ended March 31, 2025, were $23.9 million, a decrease of 24.8% compared to $31.7 million for the same period in 2024[44]. - Clinical and development costs decreased by $7.0 million to $10.5 million, primarily due to the completion of manufacturing clinical trial materials for evorpacept[133]. - The company expects to incur significant expenses and increasing operating losses in the foreseeable future due to ongoing research and development activities[114]. - The company is developing ALX2004, a novel EGFR-targeted antibody-drug conjugate (ADC), which is designed to overcome limitations of earlier-generation EGFR-targeted ADCs[97]. Stock and Financing - The weighted-average shares of common stock used to compute net loss per share increased from 50,120,758 in Q1 2024 to 53,359,338 in Q1 2025, an increase of about 6.0%[18]. - The Company raised approximately $30 million through the sale of 2,404,855 shares under its at-the-market equity offering program as of March 31, 2025[65]. - The company completed a follow-on public offering in October 2023, raising approximately $58.9 million in net proceeds[147]. - The company expects to finance operations through equity offerings, debt financings, and collaborations, with a focus on raising additional capital[140]. - The company has a secured term loan facility of up to $100 million, with an initial draw of $10 million and future maturities totaling $10,600,000 as of March 31, 2025[60][62]. Clinical Trials and Product Development - The lead product candidate, evorpacept, demonstrated an overall response rate (ORR) of 41.3% in the intent-to-treat population in the ASPEN-06 Phase 2 clinical trial, compared to 30% for the historical control[94]. - In the same trial, evorpacept showed a median duration of response (mDOR) of 15.7 months and a median progression-free survival (mPFS) of 7.5 months, outperforming the control group[94]. - Evorpacept demonstrated a confirmed overall response rate (ORR) of 52% in the Evo-TRP treatment arm compared to 22% for the TRP control arm in the interim Phase 2 clinical data from the ASPEN-06 trial[99]. - The ASPEN-07 trial reported an unconfirmed ORR of 59% for evorpacept plus enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer[106]. - The company filed an IND application for ALX2004 in March 2025, which was cleared by the FDA in April 2025 for a Phase 1 clinical trial[112]. Operational Challenges - The company has not generated any revenue from product sales, licenses, or collaborations to date, and is heavily reliant on the success of its lead product candidate, evorpacept[176]. - The company has encountered setbacks in clinical trials, including the failure to meet primary endpoints in recent trials, which may impact future development[196]. - The company anticipates ongoing challenges in clinical trial enrollment due to factors such as COVID-19 and competition for eligible subjects[202]. - The company must navigate various regulatory requirements and potential delays in clinical trials, which could hinder the commercialization of its product candidates[194]. - The company has faced delays in clinical trial enrollment and retention, which could impact regulatory submissions and marketing approvals[201]. Compliance and Regulatory Issues - The company received a compliance notice from Nasdaq on April 23, 2025, regarding its common stock closing below the minimum bid price requirement of $1.00 per share for 30 consecutive business days, with a compliance period until October 20, 2025[88]. - The company has not identified any material changes to its critical accounting policies and estimates from the previous year[160]. - The company has no off-balance sheet arrangements as defined by SEC rules[158]. - The company is exposed to interest rate risk, with borrowings of $10.0 million under a Loan Agreement, which bears interest at a floating rate[164]. - The company has not experienced any realized losses on its deposits of cash, cash equivalents, or investments during the periods presented[166].

Financial Performance - The company incurred net losses of $134.9 million, $160.8 million, and $123.5 million for the years ended December 31, 2024, 2023, and 2022, respectively, with an accumulated deficit of $621.1 million as of December 31, 2024[142]. - As of December 31, 2024, the company had cash, cash equivalents, and investments of $131.3 million, which are expected to fund operations into the fourth quarter of 2026[145]. - The company will require substantial additional capital to finance its operations and may need to raise funds through public or private equity offerings, debt financings, or collaborations[144]. - As of December 31, 2024, the company had net operating loss carryforwards of approximately $162.6 million for U.S. federal income tax purposes and $69.0 million for state income tax purposes, with federal losses carrying forward indefinitely but limited to offsetting 80% of future taxable income[315]. - The company also reported Irish net operating loss carryforwards of approximately $5.5 million, which do not expire but may not be fully utilized without sufficient income generation in Ireland[316]. Product Development and Regulatory Challenges - The company has no products approved for commercial sale and has not generated any revenue from product sales, licenses, or collaborations to date[142]. - The company has a limited operating history and has not yet demonstrated the ability to successfully complete large-scale clinical trials or obtain marketing approvals[149]. - The company's ability to generate revenue and achieve profitability depends significantly on the successful development and commercialization of its product candidates[150]. - The company is heavily dependent on the success of its lead product candidate, evorpacept, which is currently in clinical development and has not completed a pivotal trial[158]. - The company has not received regulatory approval for any products and may never be able to develop marketable product candidates[158]. - Clinical trials are expensive and time-consuming, with the potential for significant delays due to various factors, including recruitment challenges and regulatory requirements[161][165]. - The company must demonstrate substantial evidence of safety and efficacy through well-controlled clinical trials before seeking regulatory approvals[161]. - The company may incur unplanned costs and face challenges in obtaining favorable coverage and reimbursement from third-party payors for its product candidates[158]. - The company is focused on obtaining, maintaining, and expanding patent protection and regulatory exclusivity for its product candidates[158]. - The company may need to conduct additional clinical trials that could be costly and time-consuming to meet regulatory requirements[205]. - The FDA's approval process is lengthy and unpredictable, potentially delaying revenue generation from product candidates[217]. Competition and Market Dynamics - The company faces substantial competition from major pharmaceutical and biotechnology companies, including AstraZeneca, Bristol Myers Squibb, and Merck, which may impact the development and commercialization of evorpacept[171]. - Competitors are developing drugs targeting the CD47 pathway, which may affect the market potential of the company's product candidates[172]. - If approved, evorpacept is expected to be priced at a significant premium over competitive generic products, potentially complicating the company's business strategy[173]. - The company's market opportunities may be limited to smaller patient subsets, which could adversely affect its business if regulatory authorities require narrower indications[205]. Operational Risks and Challenges - The company may face challenges in attracting and retaining qualified personnel, which could impact its ability to implement its business strategy[142]. - The company relies on third-party manufacturers for the production of its product candidates, which increases the risk of supply delays and quality issues[184]. - The company previously relied on Tallac Therapeutics for preclinical research activities, and any disruptions in transitioning these activities in-house could delay the development pipeline[179]. - The company faces challenges in maintaining and expanding its organization, which could hinder the development and commercialization of evorpacept and other product candidates[294]. - The company is highly dependent on key personnel, and the loss of any executive officers or key employees could result in delays in product development[296]. Legal and Compliance Issues - The company is subject to various healthcare laws and regulations, including the Civil Monetary Penalty Act and HIPAA, which impose significant compliance costs and potential penalties for violations[237]. - Non-compliance with healthcare laws could result in civil, criminal, and administrative penalties, including exclusion from government-funded healthcare programs, which may adversely affect the company's operations and financial results[238]. - The company faces risks related to employee fraud and misconduct, which could lead to regulatory sanctions and reputational harm[239]. - Compliance with environmental, health, and safety laws is critical, as violations could result in substantial fines and impair research and development efforts[240]. Intellectual Property and Patent Risks - The company's patent portfolio is relatively small compared to larger competitors, and maintaining patent protection is critical for its strategy[255]. - Changes in patent laws and interpretations may diminish the value of patents, impacting the company's ability to protect its product candidates[265]. - The company may face litigation risks related to patent infringement claims, which could materially harm its business and financial condition[284]. - The company is aware of third-party patents in the immuno-oncology field that may cover its product candidates, including U.S. patent 10,907,209 and U.S. patent application 16/118,038, which could limit its ability to pursue evorpacept in certain indications and geographies[282]. Financial and Market Conditions - The company may experience significant volatility in its stock price, influenced by factors such as clinical trial results and market conditions for biotechnology stocks[320]. - Future sales of a substantial number of shares in the public market could lead to a significant decline in the company's stock price[330]. - The company incurred significant legal, accounting, and compliance costs as a public entity, impacting management resources[334]. - The company maintains an ERP system requiring substantial investment, which is crucial for managing operations and tracking performance[335]. Future Outlook and Strategic Considerations - The company may face challenges in attracting and retaining experienced personnel due to high living costs in the San Francisco Bay Area and competition from larger biotechnology firms[298]. - The anticipated benefits of acquisitions or joint ventures may not materialize, potentially harming the company's financial condition[314]. - The company may face difficulties in integrating acquired businesses or assets, which could delay the realization of expected benefits[313].

Financial Performance - ALX Oncology reported a GAAP net loss of $29.2 million for Q4 2024, a decrease from a net loss of $45.5 million in Q4 2023, reflecting a reduction in R&D expenses[6] - Research and Development expenses for Q4 2024 were $23.5 million, down from $41.8 million in the same period last year, primarily due to decreased clinical trial material manufacturing[6] - ALX Oncology's total operating expenses for the year ended December 31, 2024, were $142.5 million, down from $170.3 million in 2023[12] - The accumulated deficit as of December 31, 2024, was $621.1 million, an increase from $486.3 million in the previous year[14] - The company utilizes non-GAAP financial measures to provide additional insights into its financial performance, which are not in accordance with GAAP[17] - Non-GAAP net loss excludes stock-based compensation expense and accretion of term loan discount and issuance costs, differing from GAAP net loss[18] - Non-GAAP financial measures may vary in calculation compared to those used by other companies, indicating potential lack of comparability[18] Cash Position - The company has cash, cash equivalents, and investments totaling $131.3 million as of December 31, 2024, which is expected to fund operations into Q4 2026[6] Clinical Trials and Results - The confirmed objective response rate (cORR) for evorpacept in HER2-positive gastric cancer was reported at 48.9%, compared to 24.5% in the control group, with a median duration of response of 15.7 months[4] - In the Phase 1b/2 trial for metastatic breast cancer, the cORR for HER2-positive patients was 55.6%, with a median progression-free survival of 7.4 months[4] - Upcoming clinical milestones include topline results from multiple Phase 2 trials anticipated in Q2 2025, focusing on head and neck squamous cell carcinoma and urothelial cancer[6] Strategic Initiatives - The company announced a strategic workforce reduction of approximately 30% to optimize resources and extend cash runway[4] - Key leadership additions include Allison Dillon as Chief Business Officer and Alan Sandler as Chief Medical Officer, enhancing the company's strategic capabilities[4]